[Abscess-forming and necrotizing aspergillus myocarditis in a surgical intensive care patient--a rare occurrence].

The case of an 89 year old patient is reported, in whom an aspergillus myocarditis was unexpectedly found at autopsy. Preoperatively, the patient showed no risk factors for an invasive mycosis. 5 days after uncomplicated surgery he developed septic shock due to peritonitis.

Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.

In human HL-60 promyelocytic leukemia cells, diazepinylbenzoic acid derivatives can exhibit either antagonistic or synergistic effects on the differentiation-inducing activities of natural or synthetic retinoids, the activity depending largely on the nature of the substituents on the diazepine ring. Thus, a benzolog of the retinoid antagonist LE135 (6), 4-(13H-10,11,12,13-tetrahydro-10, 10,13,13,15-pentamethyldinaphtho[2,3-b][1,2-e]diazepin-7-yl) benzoic acid (LE540, 17), exhibits a 1 order of magnitude higher antagonistic potential than the parental LE135 (6). In contrast, 4-[5H-2,3-(2,5-dimethyl-2,5-hexano)-5-methyldibenzo[b,e] [1,4]diazepin-11-yl]-benzoic acid (HX600, 7), a structural isomer of the antagonistic LE135 (6), enhanced HL-60 cell differentiation induced by RAR agonists, such as Am80 (2).

Action mechanism of retinoid-synergistic dibenzodiazepines.

4-[5H-2,3-(2,5-Dimethyl-2,5-hexano)-5-methyldibenzo[b,e][1,4 ]diazepin-11-yl]benzoic acid (HX600), as well as its oxa- (HX620) and thia- (HX630) analogs, enhanced the activity of retinoic acid and a receptor alpha (RAR alpha)-selective agonist Am80 in HL-60 cell differentiation assays. HX600 synergizes with Am80 by binding to, and transactivating through, the RXR subunit of the RXR-RAR heterodimer. HX600 exhibited RXR pan-agonist activity in transient transfections with a DR1-based reporter gene and synergized with RA-bound RAR alpha and RAR beta in inducing transcription from a DR5-based reporter.

[Hydrophobic modification of polyelectrolytes as solubility enhancers in preparations for parenteral administration].

Up to now there is no excipient for the solubilization of poorly watersoluble drugs that can be used without limitations in pharmaceutical preparations for intravasal application. The available surfactants show considerable hemolytic activity, cause anaphylactic reactions are chemically instable or have no sufficient solubilizing capacity. By polymerisation of non-ionic surfactants amphiphilic side-chain-polymers are obtained which show in vitro the same solubilization capacity as the monomers but exhibit practically no hemolytic activity.

[Treatment and results in severe craniocerebral trauma].

Treatment of severe craniocerebral traumas in medium and major hospitals not provided with special neurosurgical equipment requires particularly close interdisciplinary cooperation between surgeons, neurologists and anaesthesiologists. CT facilities are an essential prerequisite for best possible patient care. Patient safety during the posttraumatic and postoperative phases is improved by measuring the intracranial pressure.